The FDA also expanded the intended use for the PD‐L1 immunohistochemistry (IHC) 22C3 PharmDx assay to include its use as a companion diagnostic device for selecting patients with HNSCC for treatment with pembrolizumab. Here, CD274 is linked to head and neck squamous cell carcinoma.